Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Erythromycin plus nasogastric tube lavage vs metoclopramide plus nasogastric tube lavage UGIH‐related mortality · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin plus nasogastric tube lavage vs metoclopramide plus nasogastric tube lavage All‐cause mortality · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin plus nasogastric tube lavage vs metoclopramide plus nasogastric tube lavage Rebleeding · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Meglitinides vs sulphonylureas Adverse events other than hypoglycaemia Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Meglitinides vs sulphonylureas All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Meglitinides vs sulphonylureas Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
SGLT‐2 inhibitors vs sulphonylureas Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
SGLT‐2 inhibitors vs sulphonylureas All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
SGLT‐2 inhibitors vs sulphonylureas Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
DPP‐4 inhibitors vs sulphonylureas Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
GLP‐1 analogues inhibitors vs sulphonylureas Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
GLP‐1 analogues inhibitors vs sulphonylureas All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Insulin analogues vs biphasic insulin Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Insulin analogues vs biphasic insulin Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Telemedicine vs usual care Adverse events other than hypoglycaemia Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Telemedicine vs usual care All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Telemedicine vs usual care Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Patient education vs usual care Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Patient education vs usual care Adverse events other than hypoglycaemia Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Patient education vs usual care All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Patient education vs usual care Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Drug dosage reduction vs usual care Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Drug dosage reduction vs usual care All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Drug dosage reduction vs usual care Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Drug dosage reduction vs usual care HbA1c (%) Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
DPP‐4 inhibitors vs sulphonylureas Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
DPP‐4 inhibitors vs sulphonylureas Self‐care Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Meglitinides vs sulphonylureas Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Superoxide dismutase (SOD) vs placebo BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants at risk of developing BPD Superoxide dismutase for bronchopulmonary dysplasia in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Superoxide dismutase (SOD) vs placebo Need for supplemental oxygen (days)№ of participants: 0 (0 RCTs) · preterm infants at risk of developing BPD Superoxide dismutase for bronchopulmonary dysplasia in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Superoxide dismutase (SOD) vs placebo Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs) · preterm infants at risk of developing BPD Superoxide dismutase for bronchopulmonary dysplasia in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 1: blue‐light filtering lenses vs non‐blue‐light filtering lenses Proportion of eyes or individuals that developed macular structural changes · adults Blue‐light filtering spectacle lenses for visual performance, sleep, and macular health in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 1: blue‐light filtering lenses vs non‐blue‐light filtering lenses Colour discrimination, measured using the FM‐100 hue test · adults Blue‐light filtering spectacle lenses for visual performance, sleep, and macular health in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Assistive technology for vision improvement interventions vs usual care or attention control Number of people who experienced 1 or more hospitalisations following a fall · older people living in the community Environmental interventions for preventing falls in older people living in the community (2023) · Cochrane | no estimate extracted | NR | No studies |
Education interventions vs control (e.g. usual care) Number of people who experienced 1 or more falls requiring hospitalisation · older people living in the community Environmental interventions for preventing falls in older people living in the community (2023) · Cochrane | no estimate extracted | NR | No studies |
Education interventions vs control (e.g. usual care) Number of people who experienced 1 or more falls requiring medical attention · older people living in the community Environmental interventions for preventing falls in older people living in the community (2023) · Cochrane | no estimate extracted | NR | No studies |
Education interventions vs control (e.g. usual care) Health‐related quality of life · older people living in the community Environmental interventions for preventing falls in older people living in the community (2023) · Cochrane | no estimate extracted | NR | No studies |
Education interventions vs control (e.g. usual care) Adverse events · older people living in the community Environmental interventions for preventing falls in older people living in the community (2023) · Cochrane | no estimate extracted | NR | No studies |
Prehabilitation vs no prehabilitation Mortality · adult patients undergoing surgery for colorectal cancer Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications… (2023) · Cochrane | no estimate extracted | NR | No studies |
Prehabilitation vs no prehabilitation Safety of the programme (dropout, SAE) · adult patients undergoing surgery for colorectal cancer Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications… (2023) · Cochrane | no estimate extracted | NR | No studies |
Endovascular therapy plus conventional medical treatment vs conventional medical treatment alone Restenosis (≥ 50%) · people with symptomatic intracranial artery stenosis Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Endovascular therapy plus conventional medical treatment vs conventional medical treatment alone Health‐related quality of life · people with symptomatic intracranial artery stenosis Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
CLACfast vs CLACslow All‐cause in‐hospital mortality by 36 weeks' postmenstrual ageUnit: number of infants with event · preterm infants with respiratory dysfunction Automated oxygen delivery for preterm infants with respiratory dysfunction (2023) · Cochrane | no estimate extracted | NR | No studies |
CLACfast vs CLACslow Severe ROPUnit: number of infants with event · preterm infants with respiratory dysfunction Automated oxygen delivery for preterm infants with respiratory dysfunction (2023) · Cochrane | no estimate extracted | NR | No studies |
CLACfast vs CLACslow Neurodevelopmental outcomes at approximately 2 years' corrected age · preterm infants with respiratory dysfunction Automated oxygen delivery for preterm infants with respiratory dysfunction (2023) · Cochrane | no estimate extracted | NR | No studies |
Automated oxygen delivery vs routine manual oxygen delivery All‐cause in‐hospital mortality by 36 weeks' postmenstrual ageUnit: number of infants with event · preterm infants with respiratory dysfunction Automated oxygen delivery for preterm infants with respiratory dysfunction (2023) · Cochrane | no estimate extracted | NR | No studies |
Automated oxygen delivery vs routine manual oxygen delivery Neurodevelopmental outcomes at approximately 2 years' corrected age · preterm infants with respiratory dysfunction Automated oxygen delivery for preterm infants with respiratory dysfunction (2023) · Cochrane | no estimate extracted | NR | No studies |
Automated oxygen delivery vs enhanced manual oxygen delivery All‐cause in‐hospital mortality by 36 weeks' postmenstrual ageUnit: number of infants with event · preterm infants with respiratory dysfunction Automated oxygen delivery for preterm infants with respiratory dysfunction (2023) · Cochrane | no estimate extracted | NR | No studies |
Automated oxygen delivery vs enhanced manual oxygen delivery Severe ROPUnit: number of infants with event · preterm infants with respiratory dysfunction Automated oxygen delivery for preterm infants with respiratory dysfunction (2023) · Cochrane | no estimate extracted | NR | No studies |
Automated oxygen delivery vs enhanced manual oxygen delivery Neurodevelopmental outcomes at approximately 2 years' corrected age · preterm infants with respiratory dysfunction Automated oxygen delivery for preterm infants with respiratory dysfunction (2023) · Cochrane | no estimate extracted | NR | No studies |